Watch BCDA. Know when insiders buy.
One email the day a filing lands. Free.
BCDA
BioCardia, Inc.
1.11
+0.03 +2.78%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
69
PASS · shorts 69
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $16.8MP/E —DIV YIELD —FCF YIELD -45.06%REV TTM —NET INCOME −$7.3MNET CASH —52W 0.77 – 2.27SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$1.6M | −$1.6M | — | -0.13 | −$1.7M | $0 | −$1.7M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$2.3M | −$2.3M | — | -0.21 | −$1.7M | $3K | −$1.7M | Aug 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$2M | −$2M | — | -0.06 | −$2.5M | $6K | −$2.5M | Mar 24 |
| Q3 2025 · Sep 30 | — | — | — | −$1.5M | −$1.5M | — | -0.24 | −$1.7M | $0 | −$1.7M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$2.1M | −$2M | — | -0.40 | −$1.6M | $1K | −$1.6M | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$2.7M | −$2.7M | — | -0.59 | −$1.6M | $0 | −$1.6M | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$2.3M | −$2.3M | — | -0.25 | −$2.4M | $1K | −$2.4M | Mar 24 |
| Q3 2024 · Sep 30 | — | — | — | −$1.8M | −$1.7M | — | -0.61 | −$2.6M | $2K | −$2.6M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$1.6M | −$1.6M | — | -0.88 | −$1.3M | $3K | −$1.3M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$2.3M | −$2.3M | — | -1.35 | −$1.5M | $0 | −$1.5M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$2.1M | −$2.1M | — | -1.32 | −$1.9M | $0 | −$1.9M | Mar 26 |
| Q3 2023 · Sep 30 | — | — | — | −$2.6M | −$2.6M | — | -1.79 | −$2.4M | $0 | −$2.4M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$8.3M | −$8.2M | — | -1.23 | −$7.4M | $7K | −$7.4M | — | — |
| FY2024 · to Dec 31 | — | — | −$8M | −$7.9M | — | -2.90 | −$7.9M | $6K | −$7.9M | — | — |
| FY2023 · to Dec 31 | — | — | −$11.6M | −$11.6M | — | -8.19 | −$10M | $12K | −$10M | — | — |
| FY2022 · to Dec 31 | — | — | −$11.9M | −$11.9M | — | -0.67 | −$10.6M | $70K | −$10.6M | — | — |
| FY2021 · to Dec 31 | — | — | −$12.6M | −$12.6M | — | -0.75 | −$10.4M | $116K | −$10.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$15.5M | −$15M | — | -1.48 | −$12.4M | $32K | −$12.4M | — | — |
Every number comes from BioCardia, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.